Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema
- PMID: 39401853
- PMCID: PMC11695135
- DOI: 10.1183/13993003.00839-2024
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema
Conflict of interest statement
Conflict of interest: E. Cantu reports grants from NIH, XVIVO Inc, CareDx and Pulmocide, consultancy fees from CSL Behring and United Therapeutics, support for attending meetings from Pulmocide Ltd, and leadership roles with International Society for Heart and Lung Transplantation (Board of Directors), UNOS Lung Committee (regional representative) and FDA (consultant for device group). I.O. Rosas reports grants from Three Lakes Foundation and Boehringer Ingelheim, and consultancy fees from Genentech Roche, Boehringer Ingelheim and Avalyn Pharmaceuticals. N.J. McKenna reports support for the present study from NIH. R. San-José Estépar reports support for the present study from NHLBI, grants or contracts from Lung Biotechnology, Insmed and Boehringer Ingelheim, consulting fees from Leuko Labs and Mount Sinai, board membership of Fundación MVision, and that they are co-founder and stockholder of Quantitative Image Solutions, and hold three patents. I. Barjaktarevic reports grants from Theravance, Viatris, Aerogen, Alpha-1 Foundation, Johnny Carson's Foundation and Takeda, consultancy fees from AstraZeneca, Sanofi/Regeneron, Grifols, Verona Pharma, Inhibrx and Takeda, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca, Sanofi/Regeneron, Grifols, Verona Pharma, Inhibrx and Takeda. A.A. Wilson reports support for the present study from NIH, grants from Grifols NA and Beam Therapeutics, and a leadership role with Alpha-1 Foundation (Scientific Director). F. Polverino reports support for the present study from NHLBI (HL149744) and Baylor College of Medicine funds, grants from Victory Houston and Boehringer Ingelheim, consultancy fees from Sanofi-Regeneron, Verona Pharma, Genentech, AstraZeneca and Amgen, support for attending meetings from ATS, and leadership roles with European Respiratory Journal (Section Editor) and RCMB (program committee chair). The remaining authors have no potential conflicts of interest to disclose.
Figures
Comment in
-
Buddy, bystander or betrayer: B cells in lymphoid aggregates in AATD emphysema.Eur Respir J. 2025 Jan 2;65(1):2402163. doi: 10.1183/13993003.02163-2024. Print 2025 Jan. Eur Respir J. 2025. PMID: 39746767 No abstract available.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources